This Company Just Initiated a Quarterly Dividend: Time to Buy?
Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates. Regeneron's shares jumped by about 5% as a result.Besides the earnings beat, the drugmaker announced another bit of good news that also had the market excited. Regeneron is now a dividend-paying company. The stock has lagged the market over the last year, and that remains true after the post-earnings rise.Does Regeneron's initiation of a quarterly dividend make it worth investing in at current levels?Continue reading

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates. Regeneron's shares jumped by about 5% as a result.
Besides the earnings beat, the drugmaker announced another bit of good news that also had the market excited. Regeneron is now a dividend-paying company. The stock has lagged the market over the last year, and that remains true after the post-earnings rise.
Does Regeneron's initiation of a quarterly dividend make it worth investing in at current levels?